UCB (EBR:UCB) UCB Media Room: EULAR 2020 E-Congress

Transparency directive : regulatory news

04/06/2020 07:00

https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUb513= 9PTmAm2ORJ-2Fb7C-2B6ekDhN0Xl3BoxGQRuSZ-2FJVOKAM97YduG-2FaWZ8aui6ZNVHYcn8uRo= n36EaEn0Mq-2FXsLNFzF3y17R7IqYVfeTu9cM-2FNxhR_xDPID0vOuylFAU8fv4e60wei4JxqEG= BdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2= X9c9g1wat2CbiF-2FWhLY87OM0k5aozkLTYpSq1x0kPblSV-2BEuL63DlA8wqCzkUww-2FO-2Bg= v-2FtdagD9j3Ot4siPHDVrGeXERDW0R8wr-2FbIpA1bEVG2NuMwSjHq8SbOeCbdn5bZmew1DZTD= HmcU1hiHMSp1AgsMNTBcjQGABPQxR1uYZxtsYwcDQdgA82b1LepPfSxNlRvZaO3QRNFYfCYnMBw= TrRK0-2BpNa96EIJwSfH9Vp6OqknLrLuZ09QD1hxOE4chsiMVcM0A-3D ** UCB Shares Breadth of Innovative New Data from Rheumatology Portfolio fo= r EULAR 2020 E-Congress ------------------------------------------------------------ =C2=B7 C-OPTIMISE results give rheumatologists and patients new considerati= ons for the maintenance of remission in axial spondyloarthritis (axSpA) wit= h certolizumab pegol treatment=C2=A0 =C2=B7 Four-year results from the RAPID-axSpA study of CIMZIA^=C2=AE (certo= lizumab pegol) highlight the importance of early, effective and long-term t= reatment targeting inflammation =C2=B7 Robust, patient-reported data on UCB=E2=80=99s investigational IL-17= A and IL-17F inhibitor, bimekizumab, showcase its potential to make a meani= ngful difference for people living with ankylosing spondylitis (AS) and pso= riatic arthritis (PsA)=C2=A0 =C2=B7 Efficacy and safety of EVENITY^=C2=AE=E2=96=BC(romosozumab) evaluate= d among postmenopausal women with osteoporosis and mild-to-moderate chronic= kidney disease =C2=B7 Research unveils barriers to shared decision-making between women wi= th chronic inflammatory diseases and their specialists=C2=A0 Brussels, Belgium =E2=80=93 4 June 2020 =E2=80=93 UCB, a global biopharmace= utical company, today announced significant new data on CIMZIA^=C2=AE (cert= olizumab pegol), EVENITY^=C2=AE (romosozumab) and its investigational IL-17= A and IL-17F inhibitor, bimekizumab, that are being presented at the Annual= European Congress of Rheumatology (EULAR) 2020. With a total of 14 accepte= d abstracts and five accepted as oral presentations across multiple rheumat= ology solutions, UCB=E2=80=99s research is set to take center stage at this= year=E2=80=99s virtual congress.=C2=A0 =E2=80=9CWe are thrilled to participate in the EULAR 2020 E-Congress and sh= are important information for rheumatologists and their patients. The bread= th of data from our rheumatology portfolio shows that we are continuing to = connect innovative research to the gaps and barriers in the patient journey= , making optimal care possible for more patients every day. With our contin= ued development in axSpA and PsA, and successful launch of EVENITY in osteo= porosis, UCB has an incredibly exciting future in rheumatology,=E2=80=9D sa= id Emmanuel Caeymaex, Executive Vice President Immunology Solutions and Hea= d of US, UCB. Following are summaries of UCB abstracts accepted as oral presentations. CERTOLIZUMAB PEGOL C-OPTIMISE STUDY: DOSE REDUCTION FOR MAINTENANCE OF REMI= SSION IN axSpA The Phase 3b C-OPTIMISE study of certolizumab pegol is the first-ever rando= mized, placebo-controlled trial to compare TNF inhibitor full maintenance d= ose continuation and dose reduction with the effects of treatment withdrawa= l in patients with axSpA who achieved sustained clinical remission.^1=C2=A0= The findings presented highlight that certolizumab pegol treatment should b= e continued beyond the achievement of sustained remission. Furthermore, the= data confirm that a reduced maintenance dose can be suitable for patients = with axSpA who achieve sustained remission following 48 weeks of certolizum= ab pegol treatment, regardless of axSpA subpopulation (radiographic [r]- an= d non-radiographic [nr]- axSpA), gender or age.^1 Achievement of a state of= low disease activity or remission is key to optimizing health-related qual= ity of life in patients with axSpA. The C-OPTIMISE findings can give rheuma= tologists and patients an alternative strategy to consider for the maintena= nce of axSpA remission with certolizumab pegol treatment. The primary C-OPTIMISE outcome was remaining flare-free during the maintena= nce period, which was achieved by eight out of ten patients, regardless of = whether they took the full certolizumab pegol dose or a reduced maintenance= dose.^1 Results showed that 83.7 percent of patients on the full dose (83.= 9 percent r-axSpA and 83.3 percent nr-axSpA) and 79 percent of those on the= reduced maintenance dose (82.1 percent r-axSpA and 75.5 percent nr-axSpA) = remained flare-free.^1 Only 20.2 percent of patients randomized to placebo = remained flare-free (17.9 percent r-axSpA and 22.9 percent nr-axSpA), under= scoring the need for continued treatment after achieving sustained remissio= n.^1 Overall, five serious treatment emergent adverse events (TEAEs) were r= eported, all of which occurred in patients continuing the full certolizumab= pegol maintenance dose.^1 A full recovery was made for all five events, in= cluding the two serious TEAEs considered by the study investigator to be tr= eatment-related (one case of intestinal obstruction and one of latent tuber= culosis).^1=C2=A0 CIMZIA RAPID-axSpA STUDY: RISK REDUCTION OF SPINAL FAT LESIONS DEVELOPMENT Four-year results from the RAPID-axSpA study of CIMZIA highlight the import= ance of early, effective and long-term treatment targeting inflammation. = =C2=A0Spinal fat lesions are one of the tell-tale signs of disease progress= ion, considered to be post-inflammatory precursors to new bone formation th= at cause worsening of patient mobility and function over time.^2 RAPID-axSp= A results show that reduction of inflammation by week 12 with CIMZIA mitiga= ted the risk of developing fat lesions over four years, while inflammation = that prevailed after the start of TNF inhibition treatment was associated w= ith increased fat lesions prevalence over that time.^2=C2=A0 CIMZIA C-VIEW STUDY: REDUCTION OF ANTERIOR UVEITIS FLARES IN axSpA In addition to the above CIMZIA oral presentations, 48-week interim results= from the open-label, Phase 4 C-VIEW study of CIMZIA in axSpA will be selec= ted as a poster tour.^3 The interim analysis revealed that acute anterior u= veitis (AAU) flare rate was significantly reduced in axSpA patients with a = history of recurrent AAU during the first 48 weeks of CIMZIA treatment.^3 P= atients also experienced substantial improvements in axSpA disease activity= .^3 AAU is reported in up to 40 percent of patients with axSpA, and is asso= ciated with significant clinical burden.^3 These C-VIEW results provide imp= ortant information for axSpA patients and their rheumatologists to consider= for their treatment plans. BIMEKIZUMAB BE AGILE STUDY: PATIENT-REPORTED OUTCOMES IN AS Findings from the Phase 2b BE AGILE study of bimekizumab in ankylosing spon= dylitis (AS) showed rapid and sustained improvements in patient-reported ou= tcomes with bimekizumab treatment.^4=C2=A0Results demonstrated greater impr= ovements at week 12 in spinal pain, fatigue, morning stiffness, sleep, dise= ase activity and quality of life in bimekizumab-treated patients than those= receiving placebo.^4 Responses were further improved and maintained to wee= k 48.^4 Serious TEAEs occurred in 4.3 percent of patients, which included t= wo major adverse cardiac events considered not related to study drug.^4 Ora= l candidiasis occurred in 5.3 percent of patients and did not lead to treat= ment discontinuation.^4 The safety and efficacy of bimekizumab have not been established and it is = not approved by any regulatory authority worldwide. BARRIERS TO SHARED DECISION-MAKING WITH WOMEN New survey findings exploring barriers to shared decision-making between pa= tients and their specialists highlight some of the complex reasons why wome= n with chronic inflammatory diseases may be likely to discontinue treatment= during pregnancy, as indicated by previous research.^5=C2=A0=C2=A0 A total of 173 rheumatologists from Germany (G, n=3D55), the United Kingdom= (UK, n=3D54) and the United States (US, n=3D64) rated their level of knowl= edge and skills compared to what is expected in their role.^5 Respondents s= cored themselves as sub-optimal against the following key areas relating to= the care of women:^5 =C2=B7 Knowledge of biologic treatments licensed for women of childbearing = age (G: 25 percent; UK: 33 percent; US: 22 percent); =C2=B7 Knowledge of methods to achieve shared decision-making between physi= cians and patients (G: 34 percent; UK: 40 percent; US: 35 percent);=C2=A0 =C2=B7 Skills discussing contraceptive methods with patients (G: 58 percent= ; UK: 79 percent; US: 55 percent); =C2=B7 Skills monitoring changes in pregnancy status or child-bearing aspir= ations (G: 65 percent; UK: 65 percent; US: 51 percent); =C2=B7 Skills approaching women of reproductive age in a way that makes the= m feel comfortable discussing their health concerns (G: 46 percent; UK: 48 = percent; US: 44 percent);=C2=A0 =C2=B7 A greater proportion of male rheumatologists reported having sub-o= ptimal skills in this area, compared to female rheumatologists (52 percent = vs 30 percent, p=3D0.046). By highlighting the knowledge and skills gaps that prevent optimal shared d= ecision-making, medical learning interventions can be developed to help rhe= umatologists address the needs of women of childbearing age living with chr= onic inflammatory diseases. EVENITY (ROMOSOZUMAB) IN PATIENTS WITH MILD-TO-MODERATE IMPAIRED RENAL FUNC= TION A post-hoc analysis of the Phase 3 ARCH and FRAME studies evaluated the eff= icacy and safety of EVENITY in postmenopausal women with osteoporosis and m= ild-to-moderate renal insufficiency.^6=C2=A0=C2=A0 In ARCH, the incidence of new vertebral fractures with EVENITY versus alend= ronate at month 12 was =E2=80=93 among patients with normal renal function = (eGFR=E2=89=A590): 3.3 percent vs 7.3 percent; among patients with mild ren= al insufficiency (eGFR=E2=89=A560-89): 3.2 percent vs 3.9 percent; and amon= g patients with moderate renal insufficiency (eGFR=E2=89=A530-59): 3.4 perc= ent vs 6.2 percent.^6=C2=A0 In FRAME, the incidence of new vertebral fractures with EVENITY versus plac= ebo at month 12 was =E2=80=93 among patients with normal renal function eGF= R=E2=89=A590): 0.5 percent vs 3.0 percent; among patients with mild renal i= nsufficiency (eGFR=E2=89=A560-89): 0.4 percent vs 1.5 percent; and among pa= tients with moderate renal insufficiency (eGFR=E2=89=A530-59): 0.6 percent = vs 2.1 percent.^6=C2=A0 In both studies, the incidences of adverse events (AEs) and serious AEs wer= e similar with EVENITY treatment across different levels of renal function.= ^6=C2=A0 Across three different levels of renal function (normal, mild, moderate) EV= ENITY treatment resulted in significant bone mineral density gains (from ba= seline) and a reduction in the risk of new vertebral fractures versus contr= ol (alendronate or placebo).^6EULAR virtual presentations are available to = delegates via the congress portal: https://u7061146.ct.sendgrid.net/ls/clic= k?upn=3D4tNED-2FM8iDZJQyQ53jATUa3m-2BmH5LGf0qo5fbKqUP1LAuuyaj3hCZuWbh-2FdMi= -2BSGUq3i_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6E= FaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wat2CbiF-2FWhLY87OM0k5aozkLTY= pSq1x0kPblSV-2BEuL63DlA8wqCzkUww-2FO-2Bgv-2FtdagD9j3Ot4siPHDVrGeXERDW0R8wr-= 2FbIpA1bEVG2NuMwfrHPLHhGmP5gLXE-2Fq72F9Ej3JaPJb2GayIXraaKCB27LKKRgfvbSKbTUx= kQhZoKUUpUxTacVfOzwJBifaxkcL5x9SToYZAjVeQ7MgVvyidZn4oVbMkhsOOl6sfS9QCEo63WS= unI9iRumVLk43-2FrSmg-3D CIMZIA oral presentations: Does gender, age or subpopulation influence the maintenance of clinical rem= ission in axial spondyloarthritis following certolizumab pegol dose reducti= on? R. Landew=C3=A9, D. van der Heijde, M. Dougados, X. Baraliakos, F. Van = den Bosch, K. Gaffney, L. Bauer, B. Hoepken, N. de Peyrecave, K. Thomas, L.= Gensler The impact of persistent inflammatory changes on prevalence of fat lesions = in patients with axial spondyloarthritis treated with certolizumab pegol: 4= -year MRI results from RAPID-axSpA, X. Baraliakos, S. Kruse, S. Auteri, N. = de Peyrecave, T. Nurminen, T. Kumke, B. Hoepken, J. Braun CIMZIA posters: Reduction of anterior uveitis flares in patients with axial spondyloarthrit= is following one year of treatment with certolizumab pegol: 48-week interim= results from a 96-week open-label study, I. Van der Horst-Bruinsma, R. Van= Bentum, F. Verbraak, T. Rath, J. Rosenbaum, M. Misterska-Skora, B. Hoepken= , O. Irvin-Sellers, B. Vanlunen, L. Bauer, M. Rudwaleit Achievement of very low disease activity and remission treatment targets is= associated with reduced radiographic progression in patients with psoriati= c arthritis treated with certolizumab pegol, L.C Coates, J.F. Merola, A. Ka= vanaugh, P.J. Mease, O. Davies, O. Irvin-Sellers, T. Nurminen, D. van der H= eijde Durability of certolizumab pegol in patients with rheumatoid arthritis or p= soriasis over three years: an analysis of pooled clinical trial data, V. By= kerk, A. Gottlieb, K. Reich, Y. Tanaka, K. Winthrop, C. Popova, N. Tilt, A.= Blauvelt Certolizumab pegol in patients with rheumatoid arthritis: pooled efficacy a= nalysis of phase 3 clinical trials across baseline rheumatoid factor quarti= les, Y. Tanaka, Z. LI, N. Inanc, R. Xavier, N. Tilt, C. Cara,=C2=A0C. Saado= un, T. Takeuchi Bimekizumab oral presentation: Efficacy and safety of bimekizumab in ankylosing spondylitis: 48-week patie= nt-reported outcomes from a phase 2b, randomised, double-blind, placebo-con= trolled, dose-ranging study, D. van der Heijde, L. Gensler, A. Deodhar, X. = Baraliakos, D. Poddubnyy, A. Kivitz, M.K. Farmer, D. Baeten, N. Goldammer, J. Coarse, M. Oortgiesen, M. Dougados Bimekizumab posters and abstracts: Efficacy and safety of 108 weeks=E2=80=99 bimekizumab treatment in patients= with psoriatic arthritis: interim results from a phase 2 open-label extens= ion study, I.B. Mcinnes, J.F. Merola, P.J. Mease, L.C. Coates, P. Joshi, J.= Coarse, B. Ink, C.T Ritchlin Association between patient-reported outcomes and disease activity in bimek= izumab-treated patients with psoriatic arthritis, L. Gossec, P.J. Mease, A.= Gottlieb, A. Ogdie, D. Assudani, J. Coarse, B. Ink, L.C. Coates EVENITY oral presentation: Efficacy and safety of romosozumab among postmenopausal women with osteopor= osis and mild-to-moderate chronic kidney disease, P. Miller, J. Adachi, B. = Albergaria, A. Cheung, A. Chines, E. Gielen, B. Langdahl, A. Miyauchi, M. O= ates, I. Reid, N. Ruiz Santiago, M. Vanderkelen, W. Yang, Z. Yu Shared decision-making oral presentation: Barriers to shared decision-making with women of reproductive age affected = by chronic inflammatory diseases, S. Murray, R. Fischer-Betz, M. Augustynia= k, J. Murase, C.Nelson-Piercy, I. Vlaev, C. Ecoffet, M. Peniuta, D. Jenkins Other UCB abstracts: Awareness about family planning and pregnancy expectation among patients wi= th chronic inflammatory disease of the skin or joints, K. Schreiber, C. Joh= ansen, U. Jensen, A. Egeberg, S. Thomsen, A. Hansen, T. Laurberg, L. Skov, = L. Kristensen Tumour necrosis factor inhibitor therapy does not reduce the incidence of c= omorbidities and extra-articular manifestations in ankylosing spondylitis: = an analysis of three US claims databases, A. Deodhar, K. Winthrop, R. Bohn,= B. Chan, R. Suruki, J. Stark, H. Yun, S. Siegel, L. Chen, J. Curtis Annual diagnostic prevalence of ankylosing spondylitis (AS) in the United S= tates using Medicare and MarketScan data, J. Curtis, K. Winthrop, B. Chan, = S. Siegel, J. Stark, R. Suruki, R. Bohn, F. Xie, H. Yun, L. Chen, A. Deodhar About CIMZIA^=C2=AE in the EU/EEA In the EU, CIMZIA^=C2=AE in combination with methotrexate (MTX) is indicate= d for the treatment of moderate to severe active RA in adult patients inade= quately responsive to disease-modifying anti-rheumatic drugs (DMARDs) inclu= ding MTX.=C2=A0 CIMZIA can be given as monotherapy in case of intolerance to MTX or when co= ntinued treatment with MTX is inappropriate. CIMZIA in combination with MTX= is also indicated for the treatment of severe, active and progressive RA i= n adults not previously treated with MTX or other DMARDs. CIMZIA has been shown to reduce the rate of progression of joint damage as = measured by X-ray and to improve physical function, when given in combinati= on with MTX. CIMZIA, in combination with MTX, is also indicated for the treatment of act= ive psoriatic arthritis in adults when the response to previous DMARD thera= py has been inadequate. CIMZIA can be given as monotherapy in case of intol= erance to MTX or when continued treatment with MTX is inappropriate. CIMZIA is also indicated in the EU for the treatment of adult patients with= severe active axial spondyloarthritis (axSpA), comprising:=C2=A0 =C2=B7 Ankylosing spondylitis (AS) =E2=80=93 adults with severe active AS w= ho have had an inadequate response to, or are intolerant to non-steroidal a= nti-inflammatory drugs (NSAIDs).=C2=A0 =C2=B7 Axial spondyloarthritis (axSpA) without radiographic evidence of AS = =E2=80=93 adults with severe active axSpA without radiographic evidence of = AS but with objective signs of inflammation by elevated C-reactive protein = (CRP) and/or Magnetic Resonance Imaging (MRI) who have had an inadequate re= sponse to, or are intolerant to NSAIDs. CIMZIA is also indicated for the treatment of moderate to severe plaque pso= riasis in adults who are candidates for systemic therapy.=C2=A0 About CIMZIA^=C2=AE in Fertility, Pregnancy and Lactation in the EU/EEA =C2=A0 Women of childbearing potential The use of adequate contraception should be considered for women of childbe= aring potential. For women planning pregnancy, continued contraception may = be considered for 5 months after the last CIMZIA^=C2=AE dose due to its eli= mination rate, but the need for treatment of the woman should also be taken= into account (see below). =C2=A0 Pregnancy Data from more than 500 prospectively collected pregnancies exposed to CIMZ= IA with known pregnancy outcomes, including more than 400 pregnancies expos= ed during the first trimester, does not indicate a malformative effect of C= IMZIA. However, the available clinical experience is too limited to, with a= reasonable certainty, conclude that there is no increased risk associated = with CIMZIA administration during pregnancy. =C2=A0 Animal studies using a rodent anti-rat TNF=CE=B1 did not reveal evidence of= impaired fertility or harm to the foetus. However, these are insufficient = with respect to human reproductive toxicity. Due to its inhibition of TNF= =CE=B1, CIMZIA administered during pregnancy could affect normal immune res= ponse in the newborn. =C2=A0 CIMZIA should only be used during pregnancy if clinically needed. Pharmacok= inetic studies suggest low or negligible level of placental transfer of a h= omologue Fab-fragment of certolizumab pegol (no Fc region). =C2=A0 In a clinical study 16 women were treated with certolizumab pegol (200 mg e= very 2 weeks or 400 mg every 4 weeks) during pregnancy. Certolizumab pegol = plasma concentrations measured in 14 infants at birth were Below the Limit = of Quantification (BLQ) in 13 samples; one was 0.042 =C2=B5g/ml with an inf= ant/mother plasma ratio at birth of 0.09 percent. At Week 4 and Week 8, all= infant concentrations were BLQ. The clinical significance of low levels ce= rtolizumab pegol for infants is unknown. It is recommended to wait a minimu= m of 5 months following the mother's last CIMZIA administration during preg= nancy before administration of live or live-attenuated vaccines (e.g. BCG v= accine), unless the benefit of the vaccination clearly outweighs the theore= tical risk of administration of live or live-attenuated vaccines to the inf= ants. =C2=A0 Breastfeeding In a clinical study in 17 lactating women treated with CIMZIA, minimal tran= sfer of certolizumab pegol from plasma to breast milk was observed. The per= centage of the maternal certolizumab pegol dose reaching an infant during a= 24 hour period was estimated to 0.04 percent to 0.30 percent. In addition,= since certolizumab pegol is a protein that is degraded in the gastrointest= inal tract after oral administration, the absolute bioavailability is expec= ted to be very low in a breastfed infant. Consequently, CIMZIA can be used = during breastfeeding. =C2=A0 Cimzia^=C2=AE (certolizumab pegol) EU/EEA* Important Safety Information Cimzia^=C2=AE was studied in 4,049 patients with rheumatoid arthritis (RA) = in controlled and open label trials for up to 92 months. The commonly repor= ted adverse reactions (1-10 percent) in clinical trials with Cimzia^=C2=AE = and post-marketing were viral infections (includes herpes zoster, papilloma= virus, influenza), bacterial infections (including abscess), rash, headache= (including migraine), asthenia, leukopenia (including lymphopenia, neutrop= enia), eosinophilic disorder, pain (any sites), pyrexia, sensory abnormalit= ies, hypertension, pruritus (any sites), hepatitis (including hepatic enzym= e increase), injection site reactions, and nausea. Serious adverse reaction= s include sepsis, opportunistic infections, tuberculosis (including miliary= , disseminated and extrapulmonary), herpes zoster, lymphoma, leukaemia, sol= id organ tumours, angioneurotic oedema, cardiomyopathies (includes heart fa= ilure), ischemic coronary artery disorders, pancytopenia, hypercoagulation = (including thrombophlebitis, pulmonary embolism), cerebrovascular accident,= vasculitis, hepatitis/hepatopathy (includes cirrhosis), and renal impairme= nt/nephropathy (includes nephritis). In RA controlled clinical trials, 4.4 = percent of patients discontinued taking Cimzia=C2=AE due to adverse events = vs. 2.7 percent for placebo. Cimzia^=C2=AE was studied in 325 patients with active axial spondyloarthrit= is (axSpA) in a clinical study for up to 4 years which included a 24-week p= lacebo-controlled phase followed by a 24-week dose-blind period and a 156-w= eek open-label treatment period and in 317 patients with non-radiographic a= xial spondyloarthritis in a placebo-controlled study for 52 weeks (AS0006). Cimzia^=C2=AE was studied in 409 patients with psoriatic arthritis (PsA) in= a clinical study for up to 4 years which included a 24-week placebo-contro= lled phase followed by a 24-week dose-blind period and a 168-week open-labe= l treatment period. The safety profile for axSpA and PsA patients treated with Cimzia=C2=AE was= consistent with the safety profile in RA and previous experience with Cimz= ia^=C2=AE. Cimzia^=C2=AE was studied in 1112 patients with psoriasis in controlled and= open-label studies for up to 3 years. In the Phase III program, the initia= l and maintenance periods were followed by a 96-week open-label treatment p= eriod. The long-term safety profile of Cimzia^=C2=AE 400 mg every 2 weeks a= nd Cimzia^=C2=AE 200 mg every 2 weeks was generally similar and consistent = with previous experience with Cimzia. Cimzia^=C2=AE is contraindicated in patients with hypersensitivity to the a= ctive substance or any of the excipients, active tuberculosis or other seve= re infections such as sepsis or opportunistic infections, and moderate to s= evere heart failure. Serious infections including sepsis, tuberculosis and opportunistic infecti= ons (e.g. histoplasmosis, nocardia, candidiasis) have been reported in pati= ents receiving Cimzia^=C2=AE. Some of these events have been fatal. Before = initiation of therapy with Cimzia^=C2=AE, all patients must be evaluated fo= r both active and inactive (latent) tuberculosis infection. If active tuber= culosis is diagnosed prior to or during treatment, Cimzia^=C2=AE therapy mu= st not be initiated and must be discontinued. If latent tuberculosis is dia= gnosed, appropriate anti-tuberculosis therapy must be started before initia= ting treatment with Cimzia^=C2=AE. Reactivation of hepatitis B has occurred in patients receiving a TNF-antago= nist including Cimzia^=C2=AE who are chronic carriers of the virus (i.e. su= rface antigen positive). Some cases have had a fatal outcome. Patients shou= ld be tested for HBV infection before initiating treatment with Cimzia^=C2= =AE. Carriers of HBV who require treatment with Cimzia^=C2=AE should be clo= sely monitored and in the case of HBV reactivation Cimzia^=C2=AE should be = stopped and effective anti-viral therapy with appropriate supportive treatm= ent should be initiated. TNF antagonists including Cimzia^=C2=AE may increase the risk of new onset = or exacerbation of GL-P-CZ-axSpA-1900034 Important Safety Information Cimzi= a Revised April 2020 * EU/EEA means European Union/European Economic Area c= linical symptoms and/or radiographic evidence of demyelinating disease incl= uding multiple sclerosis; of formation of autoantibodies and uncommonly of = the development of a lupuslike syndrome; of severe hypersensitivity reactio= ns. If a patient develops any of these adverse reactions, Cimzia^=C2=AE sho= uld be discontinued and appropriate therapy instituted. With the current knowledge, a possible risk for the development of lymphoma= s, leukaemia or other malignancies in patients treated with a TNF antagonis= t cannot be excluded. Rare cases of neurological disorders, including seizu= re disorder, neuritis and peripheral neuropathy, have been reported in pati= ents treated with Cimzia=C2=AE. Adverse reactions of the haematologic system, including medically significa= nt cytopenia, have been reported with Cimzia^=C2=AE. Advise all patients to= seek immediate medical attention if they develop signs and symptoms sugges= tive of blood dyscrasias or infection (e.g., persistent fever, bruising, bl= eeding, pallor) while on Cimzia^=C2=AE. Consider discontinuation of Cimzia^= =C2=AE therapy in patients with confirmed significant haematological abnorm= alities. The use of Cimzia^=C2=AE in combination with anakinra or abatacept is not r= ecommended due to a potential increased risk of serious infections. As no d= ata are available, Cimzia^=C2=AE should not be administered concurrently wi= th live vaccines. The 14-day half-life of Cimzia=C2=AE should be taken into= consideration if a surgical procedure is planned. A patient who requires s= urgery while on Cimzia^=C2=AE should be closely monitored for infections. Please consult the full prescribing information in relation to other side e= ffects, full safety and prescribing information. European SmPC date of revision April 2020. https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUdN3E= U-2FWvZebf3RrOmE3Tk7MlrShjDNSVHpnfL6TfOxZowbuWXJCI8bbCZVOamVwH9nu7OTyWvLsHd= N1-2FyZYmHjLZqbiXDQS8oPYmUsJ6fM-2BvtFbzqdutL-2Fr2YbsSY7P8w-3D-3DYPKD_xDPID0= vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB5= 2Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wat2CbiF-2FWhLY87OM0k5aozkLTYpSq1x0kPblSV-2BE= uL63DlA8wqCzkUww-2FO-2Bgv-2FtdagD9j3Ot4siPHDVrGeXERDW0R8wr-2FbIpA1bEVG2NuMw= VlBeGapl3DKTDYWIPJuuNqTSdJkJeeFdHcTQm9hvnWrwepMPkhQ1fARxQBEElYODzEZz8Eyv-2B= msbsYZ1CC45gdObJoFo5OKmobCOUK-2FDXlqPXtTMHNPgmXjDzCp41VfJXt3isiFjNsPj14b3fz= XMhw-3D =C2=A0 CIMZIA^=C2=AE is a registered trademark of the UCB Group of Companies. About Bimekizumab Bimekizumab is an investigational humanized monoclonal IgG1 antibody that s= electively inhibits both IL-17A and IL-17F, two key cytokines that drive in= flammation and tissue damage across multiple diseases.^7=C2=A0IL-17F has ov= erlapping biology with IL-17A and can drive inflammation independently to I= L-17A.^8,9,10,11,12=C2=A0Selective inhibition of IL-17F in addition to IL-1= 7A suppresses inflammation to a greater extent than IL-17A inhibition alone= .^11,12 The safety and efficacy of bimekizumab are being evaluated across m= ultiple disease states as part of a robust clinical program. UCB plans to s= ubmit applications to regulatory authorities for approval of bimekizumab to= treat adults with moderate-to-severe plaque psoriasis in 2020. About EVENITY^=C2=AE (romosozumab)=C2=A0 Romosozumab is a bone-forming monoclonal antibody.^13=C2=A0It is designed t= o work by inhibiting the activity of sclerostin, which simultaneously resul= ts in increased bone formation and to a lesser extent decreased bone resorp= tion.^13 The romosozumab development program includes 19 clinical studies t= hat enrolled approximately 14,000 patients.^14=C2=A0Romosozumab has been st= udied for its potential to reduce the risk of fractures in an extensive glo= bal Phase 3 program that included two large fracture trials comparing romos= ozumab to either placebo or active comparator in over 11,000 postmenopausal= women with osteoporosis.^15,16=C2=A0Amgen and UCB are co-developing romoso= zumab. Important Safety Information about EVENITY^=C2=AE (romosozumab) In the EU, Romosozumab is indicated for treatment of severe osteoporosis in= postmenopausal women at high risk of fracture. Contraindications: Romosozu= mab is contraindicated in patients who are allergic to romosozumab or any o= f the excipients, who have low levels of calcium in the blood (hypocalcaemi= a), or who have a history of myocardial infarction (heart attack) or stroke= . Myocardial infarction or stroke: Heart attack and stroke have been report= ed in patients receiving Romosozumab in randomised controlled trials (uncom= mon). Treatment with Romosozumab should not be initiated in patients with a= history of heart attack or stroke. When determining whether to use Romosoz= umab for an individual patient, the presence of risk factors for cardiovasc= ular problems, including established cardiovascular disease, high blood pre= ssure, high blood fat levels, diabetes, smoking or kidney problems, should = be evaluated. Romosozumab should only be used if the prescriber and patient= agree that the benefit outweighs the risk. If a patient experiences a myoc= ardial infarction or stroke during therapy, treatment with Romosozumab shou= ld be discontinued. Hypocalcaemia: Transient hypocalcaemia has been observe= d in patients receiving Romosozumab. Hypocalcaemia should be corrected prio= r to initiating therapy with Romosozumab and patients should be monitored f= or signs and symptoms of hypocalcaemia. If any patient presents with suspec= ted symptoms of hypocalcaemia during treatment, calcium levels should be me= asured. Patients should be adequately supplemented with calcium and vitamin= D. Patients with severe renal impairment (estimated glomerular filtration = rate [eGFR] 15 to 29ml/min/1.73m2) or receiving dialysis are at greater ris= k of developing hypocalcaemia and the safety data for these patients are li= mited. Calcium levels should be monitored in these patients. Hypersensitivi= ty: Clinically significant hypersensitivity reactions, including angioedema= , erythema multiforme, and urticaria occurred in the Romosozumab group in c= linical trials. If an anaphylactic or other clinically significant allergic= reaction occurs, appropriate therapy should be initiated and use of Romoso= zumab should be discontinued. Osteonecrosis of the Jaw: Osteonecrosis of th= e jaw (ONJ) has been reported rarely in patients receiving Romosozumab. The= following risk factors should be considered when evaluating a patient=E2= =80=99s risk of developing ONJ: (1) potency of the medicinal product that i= nhibits bone resorption (the risk increases with the antiresorptive potency= of the compound), and cumulative dose of bone resorption therapy, (2) canc= er, co-morbid conditions (e.g. anaemia, coagulopathies, infection), smoking= , (3) concomitant therapies: corticosteroids, chemotherapy, angiogenesis in= hibitors, radiotherapy to head and neck, (4) poor oral hygiene, periodontal= disease, poorly fitting dentures, history of dental disease, invasive dent= al procedures e.g. tooth extractions. All patients should be encouraged to = maintain good oral hygiene and receive routine dental check-ups. Dentures s= hould fit correctly. Patients under dental treatment, or who will undergo d= ental surgery (e.g. tooth extractions) whilst being treated with Romosozuma= b should inform their doctor about their dental treatment and inform their = dentist that they are receiving Romosozumab. Patients should immediately re= port any oral symptoms such as dental mobility, pain or swelling or non-hea= ling of sores or pus discharge during treatment with Romosozumab. Patients = who are suspected of having or who develop ONJ while receiving Romosozumab = should receive care by a dentist or an oral surgeon with expertise in ONJ. = Discontinuation of Romosozumab therapy should be considered until the condi= tion resolves and contributing risk factors are mitigated where possible. A= typical Femoral Fractures: Atypical low-energy or low trauma fracture of th= e femoral shaft, which can occur spontaneously, has been reported rarely in= patients receiving Romosozumab. Any patient who presents with new or unusu= al thigh, hip, or groin pain should be suspected of having an atypical frac= ture and should be evaluated to rule out an incomplete femur fracture. Pati= ent presenting with an atypical femur fracture should also be assessed for = symptoms and signs of fracture in the contralateral limb. Interruption of R= omosozumab therapy should be considered, based on an individual benefit-ris= k assessment. Adverse Reactions: The most common adverse reactions were nas= opharyngitis (13.6 percent) and arthralgia (12.4 percent). Common adverse r= eactions included hypersensitivity, sinusitis, rash, dermatitis, headache, = neck pain, muscle spasms and injection site reactions (most frequent inject= ion site reactions were pain and erythema). Uncommon adverse reactions were= urticaria, hypocalcaemia, stroke, myocardial infarction and cataract. Fina= lly, rare side effects were serious allergic reactions which caused swellin= g of the face, throat, hands, feet, ankles or lower legs (angioedema) and a= cute skin eruption (erythema multiforme). Refer to the attached European Summary of Product Characteristics (https://= u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATUdN3EU-2FWvZe= bf3RrOmE3Tk7MlrShjDNSVHpnfL6TfOxZowbuWXJCI8bbCZVOamVwH2R2rXOUms8GNCinFGLD4A= Jip5b-2BG7gW2-2B2HZVc0ntxjV9rBWhquj4FiUZlsMiNf7Q-3D-3D-g7y_xDPID0vOuylFAU8f= v4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeo= COG9ekocVj-2F2X9c9g1wat2CbiF-2FWhLY87OM0k5aozkLTYpSq1x0kPblSV-2BEuL63DlA8wq= CzkUww-2FO-2Bgv-2FtdagD9j3Ot4siPHDVrGeXERDW0R8wr-2FbIpA1bEVG2NuMwVrOsa4PT0d= vLF7uEIOzif4iw3RAffgdgRvVmk7kMkhsZCyVq-2BehKGBtItE-2FCI2PDxbk6V-2BrFITLug17= jmn0bb2UwjYZPacTjBNRrIQV2N3-2BB92TBMm-2FHaKCgo6Q5Fe1YsIqzH2bE0dLjQETFYBj7xI= -3D for other adverse reactions and full prescribing information for EVENIT= Y^=C2=AE=E2=96=BC. =E2=96=BC This medicinal product is subject to additional monitoring. About the Amgen and UCB Collaboration Since 2004, Amgen and UCB have been working together under a collaboration = and license agreement to research, develop and market antibody products tar= geting the protein sclerostin. As part of this agreement, the two companies= continue to collaborate on the development of romosozumab for the treatmen= t of osteoporosis. This gene-to-drug project demonstrates how Amgen and UCB= are joining forces to translate a genetic discovery into a new medicine, t= urning conceptual science into a reality. CONTACT: UCB, Brussels Scott Fleming, Bone Communications, UCB, T +44 7702777378, scott.fleming@uc= b.com Laurent Schots, Media Relations, UCB, T+32.2.559.92.64, laurent.schots@ucb.= com Antje Witte, Investor Relations, UCB, T +32.2.559.94.14, antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB, T+32.2.559.9588, isabelle.ghel= lynck@ucb.com CONTACT: Amgen, Thousand Oaks Jessica Akopyan, 805-447-0974 (media)=C2=A0 Trish Hawkins, 805-447-5631 (media) Arvind Sood, 805-447-1060 (investors) About UCB=C2=A0 UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7 600 people in= approximately 40 countries, the company generated revenue of =E2=82=AC 4.9= billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow = us on Twitter: @UCB_news. Forward looking statements UCB This press release may contain forward-looking statements including, withou= t limitation, statements containing the words =E2=80=9Cbelieves=E2=80=9D, = =E2=80=9Canticipates=E2=80=9D, =E2=80=9Cexpects=E2=80=9D, =E2=80=9Cintends= =E2=80=9D, =E2=80=9Cplans=E2=80=9D, =E2=80=9Cseeks=E2=80=9D, =E2=80=9Cestim= ates=E2=80=9D, =E2=80=9Cmay=E2=80=9D, =E2=80=9Cwill=E2=80=9D, =E2=80=9Ccont= inue=E2=80=9D and similar expressions. These forward-looking statements are= based on current plans, estimates and beliefs of management. All statement= s, other than statements of historical facts, are statements that could be = deemed forward-looking statements, including estimates of revenues, operati= ng margins, capital expenditures, cash, other financial information, expect= ed legal, arbitration, political, regulatory or clinical results or practic= es and other such estimates and results. By their nature, such forward-look= ing statements are not guarantees of future performance and are subject to = known and unknown risks, uncertainties and assumptions which might cause th= e actual results, financial condition, performance or achievements of UCB, = or industry results, to differ materially from those that may be expressed = or implied by such forward-looking statements contained in this press relea= se. Important factors that could result in such differences include: the gl= obal spread and impact of COVID-19, changes in general economic, business a= nd competitive conditions, the inability to obtain necessary regulatory app= rovals or to obtain them on acceptable terms or within expected timing, cos= ts associated with research and development, changes in the prospects for p= roducts in the pipeline or under development by UCB, effects of future judi= cial decisions or governmental investigations, safety, quality, data integr= ity or manufacturing issues; potential or actual data security and data pri= vacy breaches, or disruptions of our information technology systems, produc= t liability claims, challenges to patent protection for products or product= candidates, competition from other products including biosimilars, changes= in laws or regulations, exchange rate fluctuations, changes or uncertainti= es in tax laws or the administration of such laws, and hiring and retention= of its employees. There is no guarantee that new product candidates will b= e discovered or identified in the pipeline, will progress to product approv= al or that new indications for existing products will be developed and appr= oved. Movement from concept to commercial product is uncertain; preclinical= results do not guarantee safety and efficacy of product candidates in huma= ns. So far, the complexity of the human body cannot be reproduced in comput= er models, cell culture systems or animal models. The length of the timing = to complete clinical trials and to get regulatory approval for product mark= eting has varied in the past and UCB expects similar unpredictability going= forward. Products or potential products which are the subject of partnersh= ips, joint ventures or licensing collaborations may be subject to differenc= es disputes between the partners or may prove to be not as safe, effective = or commercially successful as UCB may have believed at the start of such pa= rtnership. UCB=E2=80=99 efforts to acquire other products or companies and = to integrate the operations of such acquired companies may not be as succes= sful as UCB may have believed at the moment of acquisition. Also, UCB or ot= hers could discover safety, side effects or manufacturing problems with its= products and/or devices after they are marketed. The discovery of signific= ant problems with a product similar to one of UCB=E2=80=99s products that i= mplicate an entire class of products may have a material adverse effect on = sales of the entire class of affected products. Moreover, sales may be impa= cted by international and domestic trends toward managed care and health ca= re cost containment, including pricing pressure, political and public scrut= iny, customer and prescriber patterns or practices, and the reimbursement p= olicies imposed by third-party payers as well as legislation affecting biop= harmaceutical pricing and reimbursement activities and outcomes. Finally, a= breakdown, cyberattack or information security breach could compromise the= confidentiality, integrity and availability of UCB=E2=80=99s data and syst= ems.=C2=A0 Given these uncertainties, you should not place undue reliance on any of su= ch forward-looking statements. There can be no guarantee that the investiga= tional or approved products described in this press release will be submitt= ed or approved for sale or for any additional indications or labelling in a= ny market, or at any particular time, nor can there be any guarantee that s= uch products will be or will continue to be commercially successful in the = future. UCB is providing this information, including forward-looking statements, on= ly as of the date of this press release and it does not reflect any potenti= al impact from the evolving COVID-19 pandemic, unless indicated otherwise. = UCB is following the worldwide developments diligently to assess the financ= ial significance of this pandemic to UCB. UCB expressly disclaims any duty = to update any information contained in this press release, either to confir= m the actual results or to report or reflect any change in its forward-look= ing statements with regard thereto or any change in events, conditions or c= ircumstances on which any such statement is based, unless such statement is= required pursuant to applicable laws and regulations.=C2=A0 Additionally, information contained in this document shall not constitute a= n offer to sell or the solicitation of an offer to buy any securities, nor = shall there be any offer, solicitation or sale of securities in any jurisdi= ction in which such offer, solicitation or sale would be unlawful prior to = the registration or qualification under the securities laws of such jurisdi= ction. For further information, UCB: Corporate Communications Laurent Schots=C2=A0 Media Relations, UCB =C2=A0 T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0 Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, =C2=A0Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 Brand Communications Andrea Levin Christopher, Immunology Communications, UCB T +1.404.483.7329, andrea.christopher@ucb.com=C2=A0 =C2=A0 1. Landew=C3=A9 R, Van der Heijde D, Dougados M, et al. Maintenance of Clinica= l Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol D= ose Reduction. Ann Rheum Dis. 2020;0:1=E2=80=939. 2. Baraliakos X, Kruse S, Auteri S, et al. The impact of persistent inflamm= atory changes on prevalence of fat lesions in patients with axial spondyloa= rthritis treated with certolizumab pegol: 4-year MRI results from RAPID-axS= pA. Abstract presented at EULAR 2020. 3. Van der Horst-Bruinsma I, Van Bentum R, Verbraak F, et al. Reduction of = anterior uveitis flares in patients with axial spondyloarthritis following = one year of treatment with certolizumab pegol: 48-week interim results from= a 96-week open-label study. Abstract presented at EULAR 2020. 4. Van der Heijde D, Gensler L, Deodhar A, et al. Dual Neutralisation of in= terleukin-17A and interleukin-17F With Bimekizumab in Patients With Active = Ankylosing Spondylitis: Results From a 48-week Phase IIb, Randomised, Doubl= e-Blind, Placebo-Controlled, Dose-Ranging Study. Ann Rheum Dis. 2020;79(5):= 595-604. 5. Murray S, Fischer-Betz R, Augustyniak M, et al. Barriers to shared decis= ion-making with women of reproductive age affected by chronic inflammatory = diseases. Abstract presented at EULAR 2020. 6. Miller P, Adachi J, Albergaria B, et al. Efficacy and safety of romosozu= mab among postmenopausal women with osteoporosis and mild-to-moderate chron= ic kidney disease. Abstract presented at EULAR 2020. 7. Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bi= mekizumab, a humanized monoclonal antibody and selective dual inhibitor of = IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991-1= 001. 8. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses b= y IL-17F. J Exp Med. 2008;205(5):1063=E2=80=931075. 9. Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fo= ld: structure and activity of a novel cytokine, IL-17F, and implications fo= r receptor binding. Embo J. 2001;20(19):5332=E2=80=935341. 10. van Baarsen LG, Lebre MC, van der Coelen D, et al. Heterogeneous expres= sion pattern of interleukin 17A (IL-17A), IL-17F and their receptors in syn= ovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: poss= ible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther.= 2014;16(4):426. 11. Maroof A, Okoye R, Smallie T, et al. Bimekizumab dual inhibition of IL-= 17A and IL-17F provides evidence of IL-17F contribution to chronic inflamma= tion in disease-relevant cells. Ann Rheum Dis. 2017;76(2):213. 12. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisatio= n by bimekizumab in psoriatic arthritis: evidence from preclinical experime= nts and a randomised placebo-controlled clinical trial that IL-17F contribu= tes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523-532. 13. UCB Pharma. Evenity (romosozumab) Summary of Product Characteristics. A= vailable at: https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJ= QyQ53jATUdN3EU-2FWvZebf3RrOmE3Tk7MlrShjDNSVHpnfL6TfOxZowbuWXJCI8bbCZVOamVwH= 2R2rXOUms8GNCinFGLD4AJip5b-2BG7gW2-2B2HZVc0ntxjzGgWC6r3TjUeWGZr1SEA8w-3D-3D= _ue9_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqd= dW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wat2CbiF-2FWhLY87OM0k5aozkLTYpSq1x= 0kPblSV-2BEuL63DlA8wqCzkUww-2FO-2Bgv-2FtdagD9j3Ot4siPHDVrGeXERDW0R8wr-2FbIp= A1bEVG2NuMwZBK72LBm5mfGxtoWDd1-2F-2Bw5TTJ0ZUyLs8Ll-2FQEAM1zuPz8nJfx-2FLgqeE= m2zrRHjkNUWriZCYxE9Q-2Fu9Pr-2ByQQTZ-2BLJmktKzuWKJtwUxqtmIEsgQi8pmlp8IwBmhL5= EgoWlA-2FDqvaroAAY9Ck7wE5To-3D Last accessed: June 2020. 14. EVENITY Advisory Committee Briefing Book 2019. Available at https://u70= 61146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jATURCR3fbVNBzIoxGp= ITHwfGmSPptQeq9K5rI-2BYTKnloQs8GpPJngqrTS0SeoEsfy-2FZg-3D-3DCYAd_xDPID0vOuy= lFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf= -2FOeoCOG9ekocVj-2F2X9c9g1wat2CbiF-2FWhLY87OM0k5aozkLTYpSq1x0kPblSV-2BEuL63= DlA8wqCzkUww-2FO-2Bgv-2FtdagD9j3Ot4siPHDVrGeXERDW0R8wr-2FbIpA1bEVG2NuMwTT4M= 2b0SvFBjnaehjNThx6txHz7lhzXjWG9uONkWo14qo3xHSU-2F0iuindz55BRiO-2Bs7o8c14zgn= yHnV8qxfQsDMfqQI2P-2FX4ruFWo487Zcoqf-2F4p-2BKhjbJFTFpvsekN88fIsXwo-2F1Z5gFr= Re4bV8Xs-3D Last accessed: June 2020. 15. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in pos= tmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532-1543. 16. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for f= racture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1= 417-1427. GenericFile EULAR 2020 Press Release FINAL (https://u7061146.ct.sendgrid.net/ls/click?u= pn=3D4tNED-2FM8iDZJQyQ53jATUb5139PTmAm2ORJ-2Fb7C-2B6ekDhN0Xl3BoxGQRuSZ-2FJV= OKxvJ3kc7P-2F0RgfNDRUBjmChxaT-2BL16uhTwnETF27q0MU-3DlNu3_xDPID0vOuylFAU8fv4= e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvPs6EFaZqddW-2FBZlGB52Zlf-2FOeoCO= G9ekocVj-2F2X9c9g1wat2CbiF-2FWhLY87OM0k5aozkLTYpSq1x0kPblSV-2BEuL63DlA8wqCz= kUww-2FO-2Bgv-2FtdagD9j3Ot4siPHDVrGeXERDW0R8wr-2FbIpA1bEVG2NuMwc6USbPMkUx-2= FKVzhLEkHIvjFvJsgxUaZUCetbp-2BgGFN6hKlUvaa8gu4FMtBMIaosVjGsKW3MuB2mcSoMFBFw= ZrH2UGK8emgPCx-2BeAXRIZDC4GVbxxxSIXEcl6qgb7EkTeBDRLXTuidrFGYkSqBMpV44-3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3D4tNED-2FM8iDZJQyQ53jAT= UeYfdhr1xEBQnaPhR2RKx1tfe2VKDZTewv5u80JomRcXVaLGqubZmBghmB7FhNGbOyDok8DoNHS= KrH8P-2FDu65jp6ydNKNwJfw5yO0xeUfuSejTJ8wZx4M12-2FZXhvQSHBj4c5MwyAoHGMuMERa8= lsiZM-3Dn1aF_xDPID0vOuylFAU8fv4e60wei4JxqEGBdVWu7KiDwjI3b8sYN46DL86bSl0KxvP= s6EFaZqddW-2FBZlGB52Zlf-2FOeoCOG9ekocVj-2F2X9c9g1wat2CbiF-2FWhLY87OM0k5aozk= LTYpSq1x0kPblSV-2BEuL63DlA8wqCzkUww-2FO-2Bgv-2FtdagD9j3Ot4siPHDVrGeXERDW0R8= wr-2FbIpA1bEVG2NuMwdLXgOqwspqMvwoQLElNWTQ4c-2FJVMlnxEdAalVFxV54f-2BcNJtDUyN= u7MU77V4csbQZFwlGm116JG9u41U1p-2B8PgyqW-2FWN-2FNckW7ywnETSrvfKOUkDM1AIPHIOx= ebHRmcLC3cg-2BkJGhoxdwioi0hcve8-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

UCB's latest news

17/04/2024 07:01

UCB (EBR:UCB) UCB Media Room: EULAR 2020 E-Congress

Transparency directive : regulatory news

UCB's latest news

Other stories